Status:
COMPLETED
A Trial of Grazax in Subjects With Hayfever
Lead Sponsor:
ALK-Abelló A/S
Conditions:
Allergy
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The trial is performed to evaluate the efficacy and safety of specific immunotherapy with Grazax for treatment of grass pollen induced allergy.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- History of grass pollen allergy
- Positive skin prick test to grass
- Positive specific IgE to grass
- Exclusion Criteria
- FEV1 \<70% of predicted value
Exclusion
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
329 Patients enrolled
Trial Details
Trial ID
NCT00421655
Start Date
December 1 2006
End Date
October 1 2007
Last Update
June 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CompleWare Corporation
Iowa City, Iowa, United States, 52244-3090